Kissei Pharmaceutical Co., Ltd. (KSPHF)

Kissei Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	28,823	25,169	22,894	25,893	30,013	20,456
Short-Term Investments	19,931	23,485	23,039	23,706	23,139	23,998
Cash & Short-Term Investments	48,754	48,654	45,933	49,599	53,152	44,454
Cash Growth	6.23%	5.92%	-7.39%	-6.69%	19.57%	-25.50%
Receivables	27,115	28,951	27,790	22,083	21,956	23,058
Inventory	25,125	24,979	26,296	22,798	18,987	20,118
Other Current Assets	4,152	4,396	4,532	6,161	5,247	5,335
Total Current Assets	105,146	106,980	104,551	100,641	99,342	92,965
Property, Plant & Equipment	27,535	27,069	24,861	24,579	24,074	24,290
Long-Term Investments	86,132	107,544	128,910	94,034	112,574	149,365
Goodwill	-	242	309	-	-	-
Other Intangible Assets	1,970	1,652	1,683	1,507	1,569	1,640
Long-Term Deferred Tax Assets	474	566	608	433	524	585
Other Long-Term Assets	22,411	1	2	1	1	2
Total Assets	243,668	244,059	260,929	221,200	238,087	268,861
Accounts Payable	5,515	4,602	4,893	4,617	4,104	7,909
Accrued Expenses	804	2,192	1,856	1,679	1,721	1,830
Short-Term Debt	1,280	1,280	1,340	1,490	1,640	1,743
Current Income Taxes Payable	1,525	1,474	2,380	408	3,497	1,487
Other Current Liabilities	8,118	7,030	7,194	6,763	7,782	5,276
Total Current Liabilities	17,956	16,578	17,663	14,957	18,744	18,245
Long-Term Deferred Tax Liabilities	16,632	16,481	21,188	10,426	16,259	28,480
Other Long-Term Liabilities	642	673	735	812	724	786
Total Liabilities	35,437	33,934	39,795	26,387	35,908	48,909
Common Stock	24,356	24,356	24,356	24,356	24,356	24,356
Additional Paid-In Capital	24,226	24,226	24,226	24,226	24,226	24,226
Retained Earnings	129,480	131,488	127,310	125,576	118,183	109,270
Treasury Stock	-15,564	-14,520	-13,209	-12,912	-12,912	-12,911
Comprehensive Income & Other	44,588	43,453	57,344	32,653	47,532	74,373
Total Common Equity	207,086	209,003	220,027	193,899	201,385	219,314
Minority Interest	1,145	1,122	1,107	914	794	638
Shareholders' Equity	208,231	210,125	221,134	194,813	202,179	219,952
Total Liabilities & Equity	243,668	244,059	260,929	221,200	238,087	268,861
Total Debt	1,280	1,280	1,340	1,490	1,640	1,743
Net Cash (Debt)	47,474	47,374	44,593	48,109	51,512	42,711
Net Cash Growth	6.56%	6.24%	-7.31%	-6.61%	20.61%	-26.25%
Net Cash Per Share	1102.93	1086.01	985.30	1043.24	1117.03	915.25
Filing Date Shares Outstanding	41.44	41.44	44.21	45.96	46.12	46.12
Total Common Shares Outstanding	41.44	42.81	44.21	46.12	46.12	46.12
Working Capital	87,190	90,402	86,888	85,684	80,598	74,720
Book Value Per Share	4997.75	4882.67	4977.38	4204.63	4366.94	4755.71
Tangible Book Value	205,116	207,109	218,035	192,392	199,816	217,674
Tangible Book Value Per Share	4950.21	4838.42	4932.32	4171.95	4332.92	4720.15
Order Backlog	-	3,403	2,613	2,098	1,479	2,726

Source: S&P Global Market Intelligence. Standard template. Financial Sources.